Glioma

The experimental therapy iopofosine I 131 may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…

The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…

Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…

The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…

Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…

Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…

The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.

A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…

A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…